Why should you invest in this smallcase?

Indian pharmaceutical sector is estimated to grow to US$ 100 billion by 2025. Branded generics dominate the pharmaceuticals market, constituting nearly 80% of the market share in terms of revenues.

Pharma sector is expected to generate 58,000 additional job opportunities by 2025. Indian companies received 336 Abbreviated New Drug Application (ANDA) approvals from the USFDA accounting for 40% of total final ANDA approvals in 2019. A large pipe-line of high-value drugs as well as decline in regulatory alerts for larger companies is expected to drive growth.

This smallcase comprises pharmaceutical and life sciences companies to allow investors to efficiently track and invest in the pharma sector.

Know how this smallcase was created


Download key points about this smallcase

Created by Windmill Capital

Past Performance vs 

Value of ₹ 100 invested once on
inception of this smallcase

Mar 3, 2014

would be
Pharma Tracker
₹ 357.45
Equity Large & Mid Cap
₹ 385.83


Note: Past performance graph includes changes due to rebalance, events like stock splits & mergers. Also, past performance doesn't guarantee future returns